New Scientific Advisory Board Member

“John’s expertise in end-to-end drug development, especially for diabetes, will be invaluable as we progress our lead candidates into IND and clinical stages,” said Dr. Russell Dahl, Neurodon’s CEO. “John has a deep knowledge of working with regulatory agencies that will help us get to FIH studies in an expeditious manner. His expertise complements our current Scientific Advisory Board of world class scientists by bringing in global clinical approval experience that is critically important at our current stage of growth.”

Dr. Amatruda joins a Board of internationally recognized experts and pioneers in the field of Ca2+ handling and its implications in major, unmet diseases. His clinical expertise will provide an invaluable contribution to progress Neurodon’s lead pipeline compounds into the clinic. This addition also strengthens Neurodon’s position as the leader in the clinical translation of ER stress-based therapeutics to cure diseases such as diabetes, Alzheimer’s, and Parkinson’s.